The Radiochemistry and Molecular Imaging Probes (RMIP) Core Facility functions at the Intersection of the Cancer Center's laboratory research and clinical molecular Imaging initiatives - including cancer biology, medicine, chemistry, physics, radiochemistry, pharmacology and engineering, and is the largest manufacturing unit at MSKCC in terms of the number of clinical and research products produced. The RMIP Core Facility was established to provide investigators with radionuclides and to incorporate these radionuclides into radiolabeled diagnostic and/or therapeutic pharmaceuticals for both basic research investigations and patient formulations. The RMIP Core Facility consists of three major elements working closely together to provide the following services: (a) The Cyclotron Unit. Our MSKCC EBCO cyclotron on 72nd street produces 18F, 1241, 86Y and 89Zr, positron emitting radionuclides for research and clinical applications;(b) The Small Molecule Radiochemistry Section. This section incorporates cyclotron-produced positron-emitting radionuclides into radiochemicals and radiopharmaceuticals;(c) The Antibody Labeling Section. This section is responsible for the radiolabeling of peptides and monoclonal antibodies as requested by preclinical and clinical investigators for both cancer diagnostic and therapeutic purposes. MSKCC and the RMIP Core Facility have an outstanding reputation as a center for clinical translation of both imaging and therapeutic agents. Specifically, with regard to the translation of radiopharmaceuticals, over the past 20 years, the RMIP Core Facility has translated 37 radiopharmaceuticals for research clinical trials (imaging and therapy) in humans with radiolabeled antibodies, small molecules, nanoparticles and radiotherapeutics. To meet the growing programmatic demands and new federal regulations, MSKCC has implemented a significant investment In our radiochemistry facilities (to include GMP environments) over the next five years. The services provided by the RMIP Core have supported the research of 26 investigators in the past year. During the past grant period the work of the Core has contributed to 174 publications of researchers from 5 research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-48
Application #
8933547
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2014-01-01
Project End
2018-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$357,996
Indirect Cost
$156,535
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Salo-Mullen, Erin E; Lynn, Patricio B; Wang, Lu et al. (2018) Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. Fam Cancer 17:71-77
Sigel, Carlie S; Krauss Silva, Vitor Werneck; Reid, Michelle D et al. (2018) Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study. Cancer Cytopathol 126:44-53
Sauter, Craig S; Matasar, Matthew J; Schoder, Heiko et al. (2018) A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood 131:1805-1808
Berry, Sean L; Tierney, Kevin P; Elguindi, Sharif et al. (2018) Five years' experience with a customized electronic checklist for radiation therapy planning quality assurance in a multicampus institution. Pract Radiat Oncol 8:279-286
Breitbart, William (2018) Jimmie C. Holland, M.D. Psychosomatics 59:123-124
Geller, Shamir; Pitter, Ken; Moskowitz, Alison et al. (2018) Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy. Clin Lymphoma Myeloma Leuk 18:e279-e281
Romesser, Paul B; Pei, Xin; Shi, Weiji et al. (2018) Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. Int J Radiat Oncol Biol Phys 100:59-67
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Scott, Jessica M; Nilsen, Tormod S; Gupta, Dipti et al. (2018) Exercise Therapy and Cardiovascular Toxicity in Cancer. Circulation 137:1176-1191
Routy, Bertrand; Le Chatelier, Emmanuelle; Derosa, Lisa et al. (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91-97

Showing the most recent 10 out of 8799 publications